Targeting ESR1 mutations: Imlunestrant and the next chapter in ER-positive breast cancer care
Clinical Research in Oncology · 31.12.2025 · 1 (1) · 40
DOI: 10.46439/oncology.1.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Research in Oncology, online erschienen am 31.12.2025. Verfasst von Shafia Muhammad Shafiq und 2 weiteren Autor:innen. Die Arbeit nennt 6 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Around 80% of breast cancers in women aged 45 years and older are estrogen receptor–positive (ER+). Despite advances in endocrine therapy, resistance driven by ESR1 mutations remains a major clinical challenge. These mutations cause constitutive receptor activation even in estrogen-deprived environments, limiting the efficacy of aromatase inhibitors and fulvestrant. Imlunestrant (Inluriyo™) is the first FDA-approved oral selective estrogen receptor degrader (SERD) designed to overcome ESR1-mediated resistance. As a potent, brain-penetrant agent, it blocks coactivator binding and promotes proteasomal degradation of both wild-type and mutant receptors, including the resistant Y537S variant. The phase 3 EMBER-3 trial demonstrated improved progression-free survival and favorable tolerability compared with standard endocrine therapy. Imlunestrant’s oral formulation, safety profile, and ability to target ESR1 mutations mark a pivotal step toward personalized care for ER-positive, HER2-negative breast cancer. Its approval highlights the evolving landscape of precision oncology, emphasizing mutation-guided treatment selection and the potential of next-generation SERDs to reshape hormone-driven cancer management.
Zitieren
APA
Shafiq, S. M., Mehmood, S., & Habib, I. (2025). Targeting ESR1 mutations: Imlunestrant and the next chapter in ER-positive breast cancer care. Clinical Research in Oncology, 1(1), 40. https://doi.org/10.46439/oncology.1.008
Vancouver
Shafiq SM, Mehmood S, Habib I. Targeting ESR1 mutations: Imlunestrant and the next chapter in ER-positive breast cancer care. Clinical Research in Oncology. 2025;1(1):40. doi:10.46439/oncology.1.008
BibTeX
@article{Shafiq2025,
author = {Shafiq, Shafia Muhammad and Mehmood, Shehla and Habib, Iffa},
title = {Targeting ESR1 mutations: Imlunestrant and the next chapter in ER-positive breast cancer care},
journal = {Clinical Research in Oncology},
year = {2025},
volume = {1},
number = {1},
pages = {40},
doi = {10.46439/oncology.1.008}
}
EUVIMED